文献速递血脂与心血管预防冠心病

依洛尤单抗降低低密度脂蛋白胆固醇水平的个体间变异:FOURIER 试验数据分析

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
PubMed 文献 · JAMA Cardiol · 2019-01-01

本研究基于 FOURIER 随机对照试验数据,在 21 768 例接受他汀治疗的稳定性动脉粥样硬化性心血管病患者中分析依洛尤单抗降低 LDL-C 的个体间变异。结果显示第 4 周时依洛尤单抗组 LDL-C 中位降幅为 66%(IQR 54%-76%),94.7% 的患者降幅 ≥50%,提示依洛尤单抗降 LDL-C 效应高度一致且稳健。

要点

  • 依洛尤单抗第 4 周 LDL-C 中位降幅 66%,IQR 54%-76%。
  • 94.7% 患者 LDL-C 降幅 ≥50%,99.5% 有任意降幅。
  • 仅 0.5% 患者无明显 LDL-C 下降。

核心结论

  • 依洛尤单抗降低 LDL-C 的效应高度一致且稳健,个体间变异较小。

研究设计与样本

  • 基于 FOURIER 随机对照试验的事后分析,纳入接受他汀治疗的稳定性动脉粥样硬化性心血管病患者,排除基线 LDL-C 变异大、未用药、调整背景降脂治疗或无第 4 周 LDL-C 样本者后,21 768 例纳入主要分析。

主要发现

  • 第 4 周依洛尤单抗组 LDL-C 中位降幅 66%(IQR 54%-76%),基线中位值 90 mg/dL(IQR 79-105),治疗后中位值 31 mg/dL(IQR 21-44)。
  • 第一年内依洛尤单抗组 10 325/10 902 例(94.7%)LDL-C 降幅 ≥50%,10 669/10 902 例(97.9%)降幅 ≥30%,10 849/10 902 例(99.5%)有任意降幅,53 例(0.5%)无明显下降。
  • 安慰剂组第 4 周 LDL-C 中位降幅 4%(IQR 6% 升高至 13% 降低),基线中位值 90 mg/dL(IQR 79-106),治疗后中位值 87 mg/dL(IQR 74-103)。
  • 第 4 周安慰剂校正后依洛尤单抗组 LDL-C 降幅 ≥50% 者为 9 839/10 866 例(90.5%),降幅 ≥30% 者为 10 846/10 866 例(99.8%)。
  • 结果在临床相关亚组中一致。

临床怎么用

  • 依洛尤单抗可在绝大多数接受他汀治疗的稳定性动脉粥样硬化性心血管病患者中实现一致且显著的 LDL-C 降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Little is known about the heterogeneity in low-density lipoprotein cholesterol levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor medications. OBJECTIVE: To evaluate the interindividual variability in LDL-C reduction with the PCSK9 inhibitor drug evolocumab. DESIGN, SETTING, AND PARTICIPANTS: We examined the percentage change in LDL-C levels from baseline in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, a placebo-controlled randomized clinical trial of the PCSK9 inhibitor evolocumab in patients with stable atherosclerotic cardiovascular disease who were taking statin medications. Patients in either treatment arm who had high baseline LDL-C variability during screening and either did not receive the study drug, altered their background lipid-lowering therapy regimen, or had no LDL-C level sample in week 4 were excluded from the primary analysis. Analyses in the patients were stratified by treatment arm. Data was collected from 2013 to 2016, and data were analyzed from January 2018 to November 2018. MAIN OUTCOMES AND MEASURES: Interindividual variation in percent reduction in LDL-C with evolocumab. RESULTS: There were 27 564 individuals in the cohort; after exclusions for baseline variability (n = 3524) or alterations in background lipid therapy and other causes (n = 2272), 21 768 patients remained. At week 4, the median percent reduction in LDL-C levels from baseline was 66% (interquartile range, 54%-76%; median [interquartile range] baseline value, 90 [79-105] mg/dL; postchange value, 31 [21-44] mg/dL) with evolocumab. During the first year, a total of 10 325 of 10902 patients in the evolocumab group (94.7%) had a reduction 50% or greater in LDL-C levels, 10 669 of 10 902 (97.9%) had a reduction 30% or more, and 10 849 of 10 902 (99.5%) had any reduction in LDL-C levels. Fifty-three patients (0.5%) had no apparent reduction in LDL-C levels. In the placebo arm, the median LDL-C reduction was 4% (interquartile range, 6% increase to 13% reduction; baseline median [IQR] value, 90 [79-106] mg/dL; postchange value, 87 [74-103] mg/dL) at 4 weeks. Waterfall plots showed notable variability in the top and bottom 5% of patients for both evolocumab and placebo groups, with large changes in LDL-C levels in the placebo group (increases of ≥25%, 531 patients [4.9%]; decreases of ≥25%, 985 patients [9.1%]). At 4 weeks, the placebo-adjusted reductions in LDL-C levels with evolocumab were 50% or greater in 9839 of 10 866 patients (90.5%) and 30% or greater in 10 846 of 10 866 patients (99.8%). Results were consistent across clinically relevant subgroups. CONCLUSIONS AND RELEVANCE: There appears to be a highly consistent robust reduction in LDL-C levels with evolocumab use. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01764633.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Qamar A, Giugliano RP, Keech AC, et al. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA Cardiol. 2019. PMID: 30540337. doi:10.1001/jamacardio.2018.4178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。